Management of men with high genetic risk of breast cancer. Is there a place for screening or risk-reducing surgery? Case report and review.

Miao, 2011, Incidence and outcome of male breast cancer: an international population-based study, J. Clin. Oncol., 29, 4381, 10.1200/JCO.2011.36.8902 Campos, 2021, Genetic landscape of male breast cancer, Cancers (Basel), 13, 10.3390/cancers13143535 Daly, 2021, Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology, J. Natl. Compr. Canc. Netw., 19, 77, 10.6004/jnccn.2021.0001 Tsaousis, 2019, Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations, BMC Cancer, 19, 535, 10.1186/s12885-019-5756-4 https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf.NCCN. Malhotra, 2020, Genetic counseling, testing, and management of HBOC in India: an expert consensus document from indian society of medical and pediatric oncology, JCO Glob. Oncol., 6, 991, 10.1200/JGO.19.00381 Rhiem, 2022, Consensus recommendations of the german consortium for hereditary breast and ovarian cancer, Breast Care (Basel), 17, 199, 10.1159/000516376 Moretta, 2018, The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition, Bull. Cancer, 105, 907, 10.1016/j.bulcan.2018.08.003 Hallowell, 2006, Guilt, blame and responsibility: men's understanding of their role in the transmission of BRCA1/2 mutations within their family, Sociol. Health Illn., 28, 969, 10.1111/j.1467-9566.2006.00515.x Graves, 2011, BRCA1/2 genetic testing uptake and psychosocial outcomes in men, Fam. Cancer, 10, 213, 10.1007/s10689-011-9425-2 Childers, 2018, National distribution of cancer genetic testing in the United States: evidence for a gender disparity in hereditary breast and ovarian cancer, JAMA Oncol., 4, 876, 10.1001/jamaoncol.2018.0340 Pizzato, 2021, Trends in male breast cancer mortality: a global overview, Eur. J. Cancer Prev., 30, 472, 10.1097/CEJ.0000000000000651 Mathelin, 2022, [Techniques and complications of non-genetic risk reducing mastectomies: guidelines of the National College of French Gynecologists and Obstetricians (CNGOF)], Gynecol. Obstet. Fertil. Senol., 50, 121 Mathelin, 2022, [Non-genetic indications for risk reducing mastectomies: guidelines of the National College of French Gynecologists and Obstetricians (CNGOF)], Gynecol. Obstet. Fertil. Senol., 50, 107 Barnes, 2022, Breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers using polygenic risk scores, J. Natl. Cancer Inst., 114, 109, 10.1093/jnci/djab147 Tai, 2007, Breast cancer risk among male BRCA1 and BRCA2 mutation carriers, J. Natl. Cancer Inst., 99, 1811, 10.1093/jnci/djm203 Castro, 2013, Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer, J. Clin. Oncol., 31, 1748, 10.1200/JCO.2012.43.1882 Ibrahim, 2018, Male BRCA mutation carriers: clinical characteristics and cancer spectrum, BMC Cancer, 18, 179, 10.1186/s12885-018-4098-y Institut National du Cancer (INCa). Synthèse - Femmes porteuses d'une mutation de BRCA1 ou BRCA2 /Détection précoce du cancer du sein et des annexes et stratégies de réduction du risque. Collection Recommandations et référentiels / Recommandations de pratique clinique mai 2017. Pritzlaff, 2017, Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results, Breast Cancer Res. Treat., 161, 575, 10.1007/s10549-016-4085-4 Yang, 2020, Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families, J. Clin. Oncol., 38, 674, 10.1200/JCO.19.01907 Meijers-Heijboer, 2002, Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations, Nat. Genet., 31, 55, 10.1038/ng879 Cunha, 2021, ATM germline variants and male breast cancer, BMJ Case Rep., 14, 10.1136/bcr-2020-238100 Maguire, 2021, Common Susceptibility Loci for Male Breast Cancer, J. Natl. Cancer Inst., 113, 453, 10.1093/jnci/djaa101 Hall, 1990, Linkage of early-onset familial breast cancer to chromosome 17q21, ScienceScience, 250, 1684, 10.1126/science.2270482 Wooster, 1994, Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13, ScienceScience, 265, 2088, 10.1126/science.8091231 Maxwell, 2016, Population Frequency of Germline BRCA1/2 Mutations, J. Clin. Oncol., 34, 4183, 10.1200/JCO.2016.67.0554 Thompson, 2016, Panel testing for familial breast cancer: calibrating the tension between research and clinical care, J. Clin. Oncol., 34, 1455, 10.1200/JCO.2015.63.7454 Struewing, 1997, The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews, N. Engl. J. Med., 336, 1401, 10.1056/NEJM199705153362001 Herzog, 2021, Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America, NPJ Breast Cancer, 7, 107, 10.1038/s41523-021-00317-6 Ang, 2022, Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation in Asian patients with breast cancer, J. Clin. Oncol., 40, 1542, 10.1200/JCO.21.01647 Van der Merwe, 2022, Prevalence of clinically relevant germline BRCA variants in a large unselected South African breast and ovarian cancer cohort: a public sector experience, Front. Genet., 13, 10.3389/fgene.2022.834265 Evans, 2010, Risk of breast cancer in male BRCA2 carriers, J. Med. Genet., 47, 710, 10.1136/jmg.2009.075176 Rizzolo, 2013, Male breast cancer: genetics, epigenetics, and ethical aspects, Ann. Oncol., 24, viii75, 10.1093/annonc/mdt316 Basham, 2002, BRCA1 and BRCA2 mutations in a population-based study of male breast cancer, Breast Cancer Res., 4, R2, 10.1186/bcr419 Ottini, 2012, Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy, Breast Cancer Res. Treat., 134, 411, 10.1007/s10549-012-2062-0 Gargiulo, 2016, Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis, BMC Cancer, 16, 375, 10.1186/s12885-016-2414-y Moten, 2013, Characterizing lobular carcinoma of the male breast using the SEER database, J. Surg. Res., 185, e71, 10.1016/j.jss.2013.05.043 Paluch-Shimon, 2016, Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening, Ann. Oncol., 27, v103, 10.1093/annonc/mdw327 Gaddam, 2021, Male breast cancer risk assessment and screening recommendations in high-risk men who undergo genetic counseling and multigene panel testing, Clin. Breast Cancer, 21, e74, 10.1016/j.clbc.2020.07.014 Woods, 2020, Image-based screening for men at high risk for breast cancer: benefits and drawbacks, Clin. Imaging, 60, 84, 10.1016/j.clinimag.2019.11.005 Combi, 2020, Male bilateral risk-reducing mastectomy: report of a case, Breast J., 26, 2135, 10.1111/tbj.13928 Ryser, 2019, Cancer outcomes in DCIS patients without locoregional treatment, J. Natl. Cancer Inst., 111, 952, 10.1093/jnci/djy220 Sanders, 2015, Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up, Mod. Pathol., 28, 662, 10.1038/modpathol.2014.141